POLIVY is a type of medicine that treats relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

Who is POLIVY for?

POLIVY is an FDA-approved treatment for adults with DLBCL who have already received at least 2 prior therapies. It is used in combination with 2 other cancer treatments: bendamustine and a rituximab product.

POLIVY received an accelerated approval from the FDA. This conditional approval helps patients get earlier access to a promising drug while the company continues to conduct clinical trials to establish how well the drug works.

How does POLIVY work?

POLIVY is a type of medicine called an antibody-drug conjugate, or ADC. POLIVY is designed to work differently from traditional chemotherapies because it has the ability to find dividing B cells, including cancerous B cells.

Almost all B cells (including cancerous ones) have a marker on their surface called CD79b. POLIVY works by finding and attaching to B cells using the CD79b marker.

*Antibodies are also produced naturally by the body. They are a type of protein that acts as a natural defense system against disease.

Here is how POLIVY may work:

POLIVY™ (polatuzumab vedotin-piiq) mechanism of action to induce internalization

POLIVY delivers an anti-cancer drug to the B cell by attaching to a CD79b B cell surface marker.

POLIVY™(polatuzumab vedotin-piiq) mechanism of action to release anti-cancer drug into cell

After being taken into the B cell, POLIVY is broken down, releasing the anti-cancer drug inside the B cell.

POLIVY™ (polatuzumab vedotin-piiq) - cancer cell death, healthy b cell

Once released, the anti-cancer drug in POLIVY causes the dividing B cells to die, including the cancerous ones. It may also harm healthy cells in the body.

Talk to your doctor about possible side effects. Please also see the full Prescribing Information for a complete list of possible side effects